Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Pharmacology›Chelating Agents
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Chelating Agents

Pharmacology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

Chemicals that bind to and remove ions from solutions.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (813 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of coordination complexes with metals.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Agents, Chelating; Chelator; Chelating Agent; Agent, Chelating; Chelators; Complexons; Metal Antagonists; Antagonists, Metal.

Where it fits in the MeSH classification

Broader topics
Sequestering Agents
Narrower topics
Calcium Chelating Agents; Iron Chelating Agents
See also
Antidotes; Iron Chelating Agents

Related concepts

  • Coordination Complexes
  • Metals

Research landscape

PubMed indexes 35,959 records tagged with the MeSH heading “Chelating Agents” (counts retrieved 2026-10-29). 4,515 of them (12.6%) were published from 2020 onward, and the busiest period so far is through 1999 with 11,129 records.

Reviews account for 3,304 records (9.2%) and meta-analyses for 97. Randomized controlled trials number 571 (1.6%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 11,129 records; 2000-2009: 10,490 records; 2010-2019: 9,825 records; 2020 onward: 4,515 records11,129through 199910,4902000-20099,8252010-20194,5152020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 199911,129
2000-200910,490
2010-20199,825
2020 onward4,515
Share of records by publication typeReviews: 9.2 percent; Meta-analyses: 0.3 percent; Randomized controlled trials: 1.6 percentReviews9.2% (3,304)Meta-analyses0.3% (97)Randomized controlled trials1.6% (571)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 35,959 PubMed records
TypeRecordsShare
Reviews3,3049.2%
Meta-analyses970.3%
Randomized controlled trials5711.6%

Method: PubMed query "Chelating Agents"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in pharmacology

Drug evidence builds in layers: laboratory pharmacology describes how a compound acts, pharmacokinetic studies describe how the body handles it, and randomized trials test whether it helps and what harms it causes. Post-marketing surveillance and observational studies reveal rarer adverse effects but cannot prove causation. This page is educational and is not a recommendation to start, stop or change any medicine; decisions about treatment belong with a qualified clinician.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Microbiome convergence enables siderophore-secreting-rhizobacteria to improve iron nutrition and yield of peanut intercropped with maize
Wang N, Wang T, Chen Y, Wang M, Lu Q, Wang K, et al.
2024Research article
Design not recorded in structured metadata
70cc by
PMID 38287073 · DOI · PMC10825131
Inhibition of Slc39a14/Slc39a8 reduce vascular calcification via alleviating iron overload induced ferroptosis in vascular smooth muscle cells
Aierken Y, He H, Li R, Lin Z, Xu T, Zhang L, et al.
2024Research article
Design not recorded in structured metadata
36cc by
PMID 38812011 · DOI · PMC11138056
Nanosponge for Iron Chelation and Efflux: A Ferroptosis-Inhibiting Approach for Myocardial Infarction Therapy
Lv Q, Lin J, Huang H, Ma B, Li W, Chen J, et al.
2024Research article
Design not recorded in structured metadata
32cc by
PMID 38671590 · DOI · PMC11220697
Ferroptosis and Cuproptosis in Cancer and Neurodegeneration: A Comprehensive Review of Modulation by Iron and Copper Chelators and Related Agents
Tolbatov I, Marrone A
2026Review article
Design not recorded in structured metadata
4cc by
PMID 41897286 · DOI · PMC13024704

Microbiome convergence enables siderophore-secreting-rhizobacteria to improve iron nutrition and yield of peanut intercropped with maize [1]

Research article Wang N, Wang T, Chen Y, Wang M, Lu Q, Wang K, et al. · · 2024 · cited 70 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Intercropping has the potential to improve plant nutrition as well as crop yield.
Closing excerpt
These findings could be used to envision future intercropping practices aiming to improve plant nutrition.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (147 words)

Intercropping has the potential to improve plant nutrition as well as crop yield. However, the exact mechanism promoting improved nutrient acquisition and the role the rhizosphere microbiome may play in this process remains poorly understood. Here, we use a peanut/maize intercropping system to investigate the role of root-associated microbiota in iron nutrition in these crops, combining microbiome profiling, strain and substance isolation and functional validation. We find that intercropping increases iron nutrition in peanut but not in maize plants and that the microbiota composition changes and converges between the two plants tested in intercropping experiments. We identify a Pseudomonas secreted siderophore, pyoverdine, that improves iron nutrition in glasshouse and field experiments. Our results suggest that the presence of siderophore-secreting Pseudomonas in peanut and maize intercropped plays an important role in iron nutrition. These findings could be used to envision future intercropping practices aiming to improve plant nutrition.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38287073 · DOI · PMC10825131

Inhibition of Slc39a14/Slc39a8 reduce vascular calcification via alleviating iron overload induced ferroptosis in vascular smooth muscle cells [2]

Research article Aierken Y, He H, Li R, Lin Z, Xu T, Zhang L, et al. · · 2024 · cited 36 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundVascular calcification (VC) is an independent risk factor for cardiovascular diseases.
Closing excerpt
ConclusionsOur research demonstrates that iron overload occurs during VC, and that inhibition of Slc39a14 and Slc39a8 significantly relieves VC by intercepting iron overload-induced ferroptosis in VSMCs, providing new insights into the VC treatment.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (260 words)

BackgroundVascular calcification (VC) is an independent risk factor for cardiovascular diseases. Recently, ferroptosis has been recognised as a novel therapeutic target for cardiovascular diseases. Although an association between ferroptosis and vascular calcification has been reported, the role and mechanism of iron overload in vascular calcification are still poorly understood. Specifically, further in-depth research is required on whether metalloproteins SLC39a14 and SLC39a8 are involved in ferroptosis induced by iron overload.MethodsR language was employed for the differential analysis of the dataset, revealing the correlation between ferroptosis and calcification. The experimental approaches encompassed both in vitro and in vivo studies, incorporating the use of iron chelators and models of iron overload. Additionally, gain- and loss-of-function experiments were conducted to investigate iron's effects on vascular calcification comprehensively. Electron microscopy, immunofluorescence, western blotting, and real-time polymerase chain reaction were used to elucidate how Slc39a14 and Slc39a8 mediate iron overload and promote calcification.ResultsFerroptosis was observed in conjunction with vascular calcification (VC); the association was consistently confirmed by in vitro and in vivo studies. Our results showed a positive correlation between iron overload in VSMCs and calcification. Iron chelators are effective in reversing VC and iron overload exacerbates this process. The expression levels of the metal transport proteins Slc39a14 and Slc39a8 were significantly upregulated during calcification; the inhibition of their expression alleviated VC. Conversely, Slc39a14 overexpression exacerbates calcification and promotes intracellular iron accumulation in VSMCs.ConclusionsOur research demonstrates that iron overload occurs during VC, and that inhibition of Slc39a14 and Slc39a8 significantly relieves VC by intercepting iron overload-induced ferroptosis in VSMCs, providing new insights into the VC treatment.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38812011 · DOI · PMC11138056

Nanosponge for Iron Chelation and Efflux: A Ferroptosis-Inhibiting Approach for Myocardial Infarction Therapy [3]

Research article Lv Q, Lin J, Huang H, Ma B, Li W, Chen J, et al. · · 2024 · cited 32 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Myocardial infarction (MI), a consequence of coronary artery occlusion, triggers the degradation of ferritin, resulting in elevated levels of free iron in the heart and thereby inducing ferroptosis.
Closing excerpt
This study reveals a nanosponge-based nanomedicine targeting myocardial ferroptosis with efficient iron chelation and efflux, offering a promising MI treatment.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (201 words)

Myocardial infarction (MI), a consequence of coronary artery occlusion, triggers the degradation of ferritin, resulting in elevated levels of free iron in the heart and thereby inducing ferroptosis. Targeting myocardial ferroptosis through the chelation of excess iron has therapeutic potential for MI treatment. However, iron chelation in post ischemic injury areas using conventional iron-specific chelators is hindered by ineffective myocardial intracellular chelation, rapid clearance, and high systemic toxicity. A chitosan-desferrioxamine nanosponge (CDNS) is designed by co-crosslinking chitosan and deferoxamine through noncovalent gelation to address these challenges. This architecture facilitates direct iron chelation regardless of deferoxamine (DFO) release due to its sponge-like porous hydrogel structure. Upon cellular internalization, CDNS can effectively chelate cellular iron and facilitate the efflux of captured iron, thereby inhibiting ferroptosis and associated oxidative stress and lipid peroxidation. In MI mouse models, myocardial injection of CDNS promotes sustainable retention and the suppression of ferroptosis in the infarcted heart. This intervention improves cardiac function and alleviates adverse cardiac remodeling post-MI, leading to decreased oxidative stress and the promotion of angiogenesis due to ferroptosis inhibition by CDNS in the infarcted heart. This study reveals a nanosponge-based nanomedicine targeting myocardial ferroptosis with efficient iron chelation and efflux, offering a promising MI treatment.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38671590 · DOI · PMC11220697

Ferroptosis and Cuproptosis in Cancer and Neurodegeneration: A Comprehensive Review of Modulation by Iron and Copper Chelators and Related Agents [4]

Review article Tolbatov I, Marrone A · · 2026 · cited 4 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Dysregulation of iron and copper homeostasis is a pivotal driver of regulated cell death through two distinct yet interconnected modalities: ferroptosis and cuproptosis.
Closing excerpt
By delineating the molecular machinery of iron and copper metabolism, this article provides a roadmap for leveraging regulated cell death to overcome apoptosis resistance in cancer and preserve neural integrity in chronic degeneration.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (205 words)

Dysregulation of iron and copper homeostasis is a pivotal driver of regulated cell death through two distinct yet interconnected modalities: ferroptosis and cuproptosis. This comprehensive review evaluates the therapeutic modulation of these metal-driven pathways within a dual paradigm: their deployment as a cytotoxic weapon in oncology and their inhibition for neuroprotection. We synthesize evidence ranging from small-molecule synergy to advanced nanomedicine, examining how the interplay between iron and copper governs cellular fate in resistant malignancies and neurodegenerative diseases such as Parkinson's disease and Multiple Sclerosis. In oncology, bimetallic nanoplatforms and CRISPR-Cas9 nano-ionophores exploit "iron addiction" and metabolic vulnerabilities to induce fatal lipid peroxidation and FDX1-mediated proteotoxic stress, often by circumventing efflux transporters like ATP7A/B. Conversely, neuroprotective strategies focus on site-specific chelation, utilizing brain-penetrant molecules like SK4 (targeting the LAT1 transporter) and radical trapping antioxidants like CuII(atsm). Importantly, we elucidate the "iron trap" mechanism, where copper deficiency inactivates multicopper ferroxidases-including ceruloplasmin and hephaestin-thereby triggering iron-dependent ferroptosis. Our analysis reveals a self-amplifying cycle of oxidative damage driven by metal-induced ATP depletion and glutathione exhaustion. By delineating the molecular machinery of iron and copper metabolism, this article provides a roadmap for leveraging regulated cell death to overcome apoptosis resistance in cancer and preserve neural integrity in chronic degeneration.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41897286 · DOI · PMC13024704

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Bacterial siderophores in community and host interactions [5]
    Kramer J, Özkaya Ö, Kümmerli R · Nat Rev Microbiol · 2020 · cited 741 times (Europe PMC)
  • Research article Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters [6]
    Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. · Kidney Int · 2017 · cited 705 times (Europe PMC)
  • Research article Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli [7]
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. · Drugs · 2019 · cited 354 times (Europe PMC)
  • Research article Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin [8]
    Sato T, Yamawaki K · Clin Infect Dis · 2019 · cited 323 times (Europe PMC)
  • Research article Heavy metal toxicity: An update of chelating therapeutic strategies [9]
    Kim JJ, Kim YS, Kumar V · J Trace Elem Med Biol · 2019 · cited 292 times (Europe PMC)
  • Research article Iron and liver fibrosis: Mechanistic and clinical aspects [10]
    Mehta KJ, Farnaud SJ, Sharp PA · World J Gastroenterol · 2019 · cited 227 times (Europe PMC)

References

  1. Wang N, Wang T, Chen Y, Wang M, Lu Q, Wang K, et al.. Microbiome convergence enables siderophore-secreting-rhizobacteria to improve iron nutrition and yield of peanut intercropped with maize. . 2024. PMID 38287073 · DOI · PMC10825131
  2. Aierken Y, He H, Li R, Lin Z, Xu T, Zhang L, et al.. Inhibition of Slc39a14/Slc39a8 reduce vascular calcification via alleviating iron overload induced ferroptosis in vascular smooth muscle cells. . 2024. PMID 38812011 · DOI · PMC11138056
  3. Lv Q, Lin J, Huang H, Ma B, Li W, Chen J, et al.. Nanosponge for Iron Chelation and Efflux: A Ferroptosis-Inhibiting Approach for Myocardial Infarction Therapy. . 2024. PMID 38671590 · DOI · PMC11220697
  4. Tolbatov I, Marrone A. Ferroptosis and Cuproptosis in Cancer and Neurodegeneration: A Comprehensive Review of Modulation by Iron and Copper Chelators and Related Agents. . 2026. PMID 41897286 · DOI · PMC13024704
  5. Kramer J, Özkaya Ö, Kümmerli R. Bacterial siderophores in community and host interactions. Nat Rev Microbiol. 2020. PMID 31748738 · DOI · PMC7116523
  6. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al.. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017. PMID 28646995 · DOI
  7. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al.. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs. 2019. PMID 30712199 · DOI
  8. Sato T, Yamawaki K. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin. Clin Infect Dis. 2019. PMID 31724047 · DOI · PMC6853759
  9. Kim JJ, Kim YS, Kumar V. Heavy metal toxicity: An update of chelating therapeutic strategies. J Trace Elem Med Biol. 2019. PMID 31109617 · DOI
  10. Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects. World J Gastroenterol. 2019. PMID 30774269 · DOI · PMC6371002

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • SiderophoresPharmacology
  • Alkylating AgentsPharmacology
  • Cholinesterase InhibitorsPharmacology
  • Muscarinic AntagonistsPharmacology
  • Protein Synthesis InhibitorsPharmacology
  • Adrenergic AntagonistsPharmacology

All 99 articles in Pharmacology →

At a glance

35,959
PubMed records on this heading
13%
published since 2020
3,304
review articles
571
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • SiderophoresPharmacology
  • Alkylating AgentsPharmacology
  • Cholinesterase InhibitorsPharmacology
  • Muscarinic AntagonistsPharmacology
  • Protein Synthesis InhibitorsPharmacology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support